M C Irizarry1, Y Yao, B T Hyman, J H Growdon, D Praticò. 1. Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital, Boston, MA, USA. michael.c.irizarry@gsk.com
Abstract
BACKGROUND: Oxidative damage is implicated in the pathophysiology of Alzheimer's disease (AD). F2-isoprostane is a marker of lipid peroxidation which is elevated in AD CSF. Plasma F2-isoprostane has been proposed as a diagnostic marker for AD and mild cognitive impairment (MCI). OBJECTIVE: To determine whether plasma F2-isoprostane levels differ between nondemented control individuals and patients with AD, MCI, or Parkinson's disease (PD). METHODS: We collected plasma from191 outpatients with a diagnosis of AD (49), MCI (47), nondemented PD (47), and no dementia (48). Plasma levels of the isoprostane iP2alpha-IV (F2A) were determined by gas chromatography/mass spectroscopy. RESULTS: Mean plasma levels of F2A isoprostane did not differ significantly between the four diagnostic groups. Within the MCI and AD groups, F2A levels did not correlate with duration of memory impairment or with cognitive test scores. F2A levels were marginally lower in users of cholinesterase inhibitors and individuals with an APOE epsilon4 allele. CONCLUSIONS: While CSF isoprostane levels are elevated in AD, plasma isoprostane measures were neither sensitive nor specific for the clinical diagnosis of MCI or AD. Copyright (c) 2007 S. Karger AG, Basel.
BACKGROUND: Oxidative damage is implicated in the pathophysiology of Alzheimer's disease (AD). F2-isoprostane is a marker of lipid peroxidation which is elevated in AD CSF. Plasma F2-isoprostane has been proposed as a diagnostic marker for AD and mild cognitive impairment (MCI). OBJECTIVE: To determine whether plasma F2-isoprostane levels differ between nondemented control individuals and patients with AD, MCI, or Parkinson's disease (PD). METHODS: We collected plasma from191 outpatients with a diagnosis of AD (49), MCI (47), nondemented PD (47), and no dementia (48). Plasma levels of the isoprostane iP2alpha-IV (F2A) were determined by gas chromatography/mass spectroscopy. RESULTS: Mean plasma levels of F2A isoprostane did not differ significantly between the four diagnostic groups. Within the MCI and AD groups, F2A levels did not correlate with duration of memory impairment or with cognitive test scores. F2A levels were marginally lower in users of cholinesterase inhibitors and individuals with an APOE epsilon4 allele. CONCLUSIONS: While CSF isoprostane levels are elevated in AD, plasma isoprostane measures were neither sensitive nor specific for the clinical diagnosis of MCI or AD. Copyright (c) 2007 S. Karger AG, Basel.
Authors: A J Fiocco; A M Kanaya; K M Lindquist; T B Harris; S Satterfield; E M Simonsick; L Kuller; C Rosano; K Yaffe Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2010-09-25 Impact factor: 4.006
Authors: Luis F Gonzalez-Cuyar; Joshua A Sonnen; Kathleen S Montine; C Dirk Keene; Thomas J Montine Journal: Curr Neurol Neurosci Rep Date: 2011-10 Impact factor: 5.081
Authors: Orest Hurko; Kurt Boudonck; Cathleen Gonzales; Zoe A Hughes; J Steve Jacobsen; Peter H Reinhart; Daniel Crowther Journal: Int J Alzheimers Dis Date: 2010-10-11
Authors: Joshua A Sonnen; John C Breitner; Mark A Lovell; William R Markesbery; Joseph F Quinn; Thomas J Montine Journal: Free Radic Biol Med Date: 2008-04-24 Impact factor: 7.376
Authors: Chidi N Obasi; Karen J Cruickshanks; David M Nondahl; Barbara E K Klein; Ronald Klein; F Javier Nieto; Anoop Shankar; Mary E Fischer; Michael Y Tsai; Rick Chappell Journal: Oxid Antioxid Med Sci Date: 2012-06-26
Authors: Joshua A Sonnen; Kathleen S Montine; Joseph F Quinn; Jeffrey A Kaye; John C S Breitner; Thomas J Montine Journal: Lancet Neurol Date: 2008-08 Impact factor: 44.182